Hydab Capsule

Hydroxyurea (Hydroxycarbamide)
500mg
DABUR INDIA LTD.
Pack size
Dispensing mode
Source
Agent
Retail Price 24.13 NPR

Indications

Hydab Capsule is used for: Chronic myeloid leukaemia, Psoriasis, Myeloproliferative disorders, Sickle-cell disease, Essential thrombocythemia, AIDS

Adult Dose

Solid Tumors Intermittent Therapy: 80 mg/kg PO q3day, OR Continuous Therapy: 20-30 mg/kg PO qDay Head & Neck Tumors Concomitant therapy with irradiation 80 mg/kg PO q3days Begin 7 days prior to initiation of irradiation Chronic Myelocytic Leukemia, Resistant Continuous Therapy: 20-30 mg/kg PO qDay Sickle Cell Disease Start: 15 mg/kg/day as single dose; monitor patient’s blood count every two weeks Titrate by 5 mg/kg/day q12wk Dose is not increased if blood counts are between acceptable range and toxic Not to exceed 35 mg/kg/day Discontinue therapy until hematologic recovery if blood counts are considered toxic; may resume treatment after reducing dose by 2.5 mg/kg/day from dose associated with hematological toxicity Thrombocythemia, Essential 15 mg/kg PO qDay Titrate to control platelets & maintain WBC count

Child Dose

Oral Sickle-cell disease Child: 1-18 yr: 10-20 mg/kg/day, increased by 5 mg/kg/day every 12 wk according to response and blood counts.

Renal Dose

Renal impairment: Dose reduction may be needed.

Administration

Contra Indications

Severe bone-marrow suppression, severe anaemia, WBC <3000/mm3 or platelet count <100,000/mm3. Pregnancy and lactation. Hypersensitivity.

Precautions

Regular monitoring of uric acid concentrations, blood counts, renal and hepatic function is recommended. Prior irradiation therapy. Elderly. Avoid use of live vaccines. Lactation: excreted in breast milk, do not nurse

Pregnancy-Lactation

Interactions

Impairs immune response to vaccines; possible infection with live vaccines, zidovudine, zalcitabine. May alter action of oral anticoagulants and phenytoin. Potentially Fatal: Fluorouracil may increase potential for neurotoxicity. Modulates metabolism and cytotoxicity of cytarabine. May precipitate didanosine- or stavudine-induced pancreatitis, hepatotoxicity or neuropathy.

Adverse Effects

Side effects of Hydroxyurea (Hydroxycarbamide) : GI disturbances, Nausea, Vomiting, Constipation, Diarrhea, Hyperuricemia, Renal failure, Rash, Hyperpigmentation. Pulmonary oedema, dermatological reactions, headache, dizziness. Disorientation, drowsiness, hallucinations, convulsions, alopecia. Potentially Fatal: Bone marrow suppression.

Mechanism of Action

Hydroxycarbamide causes inhibition of DNA synthesis during the S-phase of cell division by acting as a ribonucleotide reductase inhibitor resulting to cell death. It is S-phase specific.

Note

Hydab 500mg Capsule manufactured by DABUR INDIA LTD.. Its generic name is Hydroxyurea (Hydroxycarbamide). Hydab is availble in Nepal. Farmaco Nepal drug index information on Hydab Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Hydroxyurea (Hydroxycarbamide) :